Yang Zhenhuan, Liu Wenjing, Zhou Xuefeng, Zhu Xiaoran, Suo Feiya, Yao Shukun
Graduate School, Beijing University of Chinese Medicine.
Department of Gastroenterology.
Medicine (Baltimore). 2020 Oct 23;99(43):e22916. doi: 10.1097/MD.0000000000022916.
Inflammatory bowel diseases (IBD), which include Crohn disease and ulcerative colitis, affect several million individuals worldwide. Curcumin as a complementary therapy has been used to cure the IBD, yet the efficacy and safety of curcumin remains to be assessed. In this study, we aim to draw up a protocol for systematic review to evaluate the efficacy and safety of curcumin for IBD.
We will search the following electronic databases from inception to September 31, 2020: PubMed, Cochrane Library, EMBASE, Web of Science, Medline, the China National Knowledge Infrastructure Database, Wan Fang Database, the Chinese Scientific Journal Database, and Chinese Biomedical Literature Database. Clinical trial registrations, potential gray literatures, relevant conference abstracts and reference list of identified studies will also be searched. Relevant randomized controlled clinical trials were enrolled and analyzed. The literature selection, data extraction, and quality assessment will be completed by 2 independent authors. Either the fixed-effects or random-effects model will be used for data synthesis based on the heterogeneity test. Clinical remission will be evaluated as the primary outcome. Clinical response, endoscopic remission, inflammatory markers and adverse events will be assessed as the secondary outcomes. The RevManV.5.3.5 will be used for Meta-analysis. Subgroup analyses of doses, delivery way, frequency of treatment and the degree of IBD severity or different forms of IBD were also conducted.
This study will provide a synthesis of current evidence of curcumin for IBD from several aspects, such as clinical remission, clinical response, endoscopic remission, inflammatory markers, and adverse events.
The conclusion of our study will provide updated evidence to judge whether curcumin is an effective solution to IBD patients.
INPLASY202090065.
炎症性肠病（IBD）包括克罗恩病和溃疡性结肠炎，全球有数百万人受其影响。姜黄素作为一种辅助疗法已被用于治疗IBD，但姜黄素的疗效和安全性仍有待评估。在本研究中，我们旨在制定一项系统评价方案，以评估姜黄素治疗IBD的疗效和安全性。
我们将检索以下电子数据库，检索时间从建库至2020年9月31日：PubMed、Cochrane图书馆、EMBASE、科学网、Medline、中国知网数据库、万方数据库、中国科学期刊数据库和中国生物医学文献数据库。还将检索临床试验注册信息、潜在的灰色文献、相关会议摘要以及已识别研究的参考文献列表。纳入并分析相关的随机对照临床试验。文献筛选、数据提取和质量评估将由2名独立作者完成。根据异质性检验，将使用固定效应模型或随机效应模型进行数据合成。将临床缓解作为主要结局进行评估。将临床反应、内镜缓解、炎症标志物和不良事件作为次要结局进行评估。将使用RevManV.5.3.5进行Meta分析。还对剂量、给药方式、治疗频率以及IBD严重程度或不同形式IBD的亚组进行了分析。
本研究将从临床缓解、临床反应、内镜缓解、炎症标志物和不良事件等多个方面综合目前关于姜黄素治疗IBD的证据。
我们研究的结论将为判断姜黄素是否是IBD患者的有效治疗方法提供最新证据。
INPLASY注册号：INPLASY202090065。
